EXHIBIT 10.14 Net Single-Tenant Laboratory 3770 Tansy/Structural GenomiX, Inc. - Page 1 LEASE AGREEMENT THIS LEASE AGREEMENT is made this 18th day of May, 2000, between ARE-3770 TANSY STREET, LLC, a Delaware limited liability company ("LANDLORD"), and...Lease Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc.
UNDERWRITING AGREEMENTSGX Pharmaceuticals, Inc. • September 2nd, 2005 • New York
23 JULY 2004SGX Pharmaceuticals, Inc. • September 2nd, 2005 • Georgia
UNDERWRITING AGREEMENTUnderwriting Agreement • January 4th, 2006 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
RECITALSIndemnity Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • Delaware
EXHIBIT 10.34 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (the "Agreement") dated September 16, 2005 by and among OXFORD FINANCE CORPORATION ("Oxford"); SILICON VALLEY BANK, a California-chartered bank, with its principal place of...Loan and Security Agreement • October 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • California
23 JULY 2004SGX Pharmaceuticals, Inc. • January 4th, 2006 • Pharmaceutical preparations • Georgia
EXHIBIT 10.13 Net Single-Tenant Laboratory 10505 Roselle Street/Protarch, Inc. - Page 1 LEASE AGREEMENT THIS LEASE AGREEMENT is made this 20th day of September, 1999, between ARE-10505 ROSELLE STREET, LLC, a Delaware limited liability company...Lease Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc.
STRUCTURAL GENOMIX, INC.Investor Rights Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • California
BACKGROUNDCollaboration Agreement • November 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
RECITALSTo Agreement • November 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
EXHIBIT 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement ("Agreement"), dated January 1, 2002, by and between Structural GenomiX, Inc., with its principal place of business at 10505 Roselle Street, San Diego, California 92121...Executive Employment Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • California
BACKGROUNDCollaboration and License Agreement • November 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Exhibit 10.31 MASTER LOAN AND SECURITY AGREEMENT NO. 2081008 DATED: AUGUST 28, 2002Master Loan and Security Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc.
EXHIBIT 4.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION...SGX Pharmaceuticals, Inc. • September 2nd, 2005 • California
1. PURPOSESGX Pharmaceuticals, Inc. • September 2nd, 2005
EXHIBIT 4.4 NEITHER THIS AMENDED AND RESTATED WARRANT NOR THE SECURITIES UNDERLYING THIS AMENDED AND RESTATED WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH...SGX Pharmaceuticals, Inc. • November 14th, 2005 • Pharmaceutical preparations • California
RECITALSAgreement • November 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
RECITALSAgreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc.
BACKGROUNDCollaboration Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • Delaware
EXHIBIT 10.36 AMENDMENT TO AGREEMENTAgreement • November 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • March 30th, 2007 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Change in Control Severance Agreement (this “Agreement”) is entered into as of December 18, 2006 (the “Effective Date”), by and between Annette North (the “Executive”) and SGX Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
EXHIBIT 10.10 SEPARATION AGREEMENT June 14, 2005 Neill Giese Dear Neill: This letter sets forth the substance of the separation agreement (the "Agreement") that STRUCTURAL GENOMIX, INC., (the "Company") is offering to you to aid in your employment...Separation Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • California
RECITALSAgreement • November 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
Agreement and Plan of Merger dated as of July 8, 2008 among Eli Lilly and Company, REM Merger Sub, Inc. and SGX Pharmaceuticals, Inc.Agreement and Plan of Merger • July 8th, 2008 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Agreement and Plan of Merger (this “Agreement”), dated as of July 8, 2008, among Eli Lilly and Company, an Indiana corporation (“Parent”), REM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and SGX Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
BACKGROUNDCollaboration and License Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • Delaware
RECITALSDrug Discovery Agreement • January 4th, 2006 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
RECITALSAgreement • November 14th, 2005 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
LEASEArticle 6 Services • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • California
March 27, 2006 LICENSE AND COLLABORATION AGREEMENT Between NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. and SGX PHARMACEUTICALS, INC.License and Collaboration Agreement • April 5th, 2006 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (“Agreement”) is made as of this 27 day of March, 2006 (the “Effective Date”) by and between Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the laws of the State of Delaware (“Novartis”) and SGX Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“SGX”). Novartis and SGX are each referred to individually as a “Party” and together as the “Parties.” Capitalized terms used but not otherwise defined herein have the meanings given to them in Section 1 hereof.
TERMINATION AGREEMENTTermination Agreement • March 13th, 2006 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
This Termination Agreement (the “Termination Agreement”) is made and entered into effective as of February 15, 2006 (the “Termination Effective Date”), by and between SGX Pharmaceuticals, Inc., (formerly known as Structural GenomiX, Inc.) a corporation incorporated under the laws of the State of Delaware and with its principal place of business located at 10505 Roselle Street, San Diego, CA 92121 (“SGX”) and Pierre Fabre Medicament S.A., (successor in interest to UroGene SA) a corporation incorporated under the laws of France with its registered office at 45, place Abel-Gance, 92654 Boulogne Cedex France (“PFM”). PFM and SGX may be referred to herein as a “Party” or, collectively, as “Parties”.
FIRST AMENDMENT TO THE DRUG DISCOVERY AGREEMENTThe Drug Discovery Agreement • March 30th, 2007 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment is entered into by and between SGX Pharmaceuticals, Inc., (formerly known as Structural GenomiX, Inc.) (“SGX”) and Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”) and is effective as of March 1, 2007 (“Amendment Effective Date”). Collectively, SGX and CFFT are referred to hereinafter as the “Parties”.
FOURTH AMENDMENT TO LEASE AGREEMENTLease Agreement • March 30th, 2007 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO LEASE AGREEMENT (this “Fourth Amendment”) is made as of March 28, 2007, by and between ARE-10505 ROSELLE STREET, LLC, a Delaware limited liability company (“Landlord”), and SGX PHARMACEUTICALS, INC., a Delaware corporation, formerly known as Structural Genomix, Inc. (“Tenant”).
RECITALSAgreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc.
AMENDMENT TO AGREEMENTTo Agreement • December 12th, 2007 • SGX Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Agreement (the “Amendment”) is made and entered into effective as of December 7, 2007 (the “Amendment Effective Date”), by and between SGX Pharmaceuticals, Inc. (formerly known as Structural GenomiX, Inc.), a corporation organized and existing under the laws of the State of Delaware and having its principal place of business located at 10505 Roselle Street, San Diego, CA 92121 (“SGX”) and Eli Lilly and Company., a corporation organized and existing under the laws of the state of Indiana and having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, (“Lilly”). Lilly and SGX may be referred to herein as a “Party” or, collectively, as “Parties”.
